NCT06618547尚未招募不适用
A Study to Investigate the Effectiveness and Safety of the TENEO 317 Model 2 Excimer Laser to Treat Myopia With or Without Astigmatism by Transepithelial Photorefractive Keratectomy
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 140
- 主要终点
- Maintenance of BCDVA -
研究概览
简要总结
A Study to Investigate the Effectiveness and Safety of the TENEO 317 Model 2 Excimer Laser to Treat Myopia with or without Astigmatism by Transepithelial Photorefractive Keratectomy
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 22 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •22 years of age or older at the time of the pre-operative examination.
- •Best distance corrected visual acuity (BCDVA) 20/25 or better in the study eye
- •Difference between manifest refractive spherical equivalent (MRSE) and the cycloplegic refraction of ≤ 0.75 D in the study eye.
- •Stable refraction (i.e., a change of ≤ 0.50 D in MRSE) for a minimum of 12 months before surgery, as verified by consecutive refractions, medical records, or prescription history.
- •Agree to discontinue contact lenses for at least two weeks (for rigid or toric lenses) or three days (for soft contact lenses) before the first refraction to establish stability and through the day of surgery.
- •A stable refraction (within ± 0.50 D) after discontinuation of contact lens(es), as determined by MRSE between two consecutive examinations at least one week apart.
- •Normal corneal topography per the investigator in the study eye.
- •Anticipated postoperative stromal thickness of at least 350 microns.
- •Ability to lie flat without difficulty.
- •Willing and able to read, understand, and sign a written informed consent form (ICF)
- •Willing and able to comply with the schedule for all post-surgery follow-up visits.
- •Pre-operative myopic refractive error with sphere component from -0.25 D to -8.00 D in each operative eye, with or without cylinder from 0.00 D to -3.00 D, based on the manifest refraction with treated MRSE of -0.25 D to -9.50 D.
排除标准
- •Acute or chronic disease or illness that would increase operative risk or confound the results of the study (e.g., dry eye, cataract, immuno-compromise, rheumatoid arthritis, clinically significant atopic disease, acne rosacea, autoimmune disease, endocrine disorders, lupus, systemic connective tissue disease, diabetes, or severe atopic disease).
- •Use of medications that may increase risk to the subject or may confound the outcome of the study, including those known to affect wound healing (e.g., systemic corticosteroids, antimetabolites)
- •Ocular conditions that may predispose the subject to future complications, including but not limited to:
- •Evidence or history of retinal vascular disease
- •History or evidence of active corneal disease or infection (e.g., recurrent corneal erosion syndrome, herpes simplex or herpes zoster keratitis) in either eye.
- •History of or evidence of glaucoma or glaucoma suspect (e.g., IOP > 21 mmHg).
- •Previous intraocular or corneal surgery in an eye considered for eligibility that might confound the study's outcome or increase the subject's risk.
- •An increased risk for developing strabismus post-treatment or an ocular muscle disorder (e.g., strabismus or nystagmus) affecting fixation.
- •Known sensitivity to any study medications (e.g., used during TransEpi PRK procedure and postoperative care).
- •Central corneal scars affecting visual acuity.
- •Presence of keratoconus, subclinical or forme fruste keratoconus, corneal dystrophy, or other corneal irregularity (e.g., irregular astigmatism).
- •Presence of visually significant or progressive cataract in an eye considered for eligibility.
- •Actively taking medications contraindicated with TransEpi PRK, such as isotretinoin (Accutane®) or amiodarone hydrochloride (Cordarone®).
- •Cardiac pacemaker, implanted defibrillator, or another implanted electronic device.
- •Pregnant, lactating, or subjects who plan to become pregnant during the study.
- •Participation in any other clinical trial within 30 days of screening or during this clinical trial.
- •Subjects for whom the pre-operative assessment of the cornea/ eyes indicates that one or both eyes are not suitable candidates for treatment based upon the investigator's medical judgment.
- •Treated eye with mesopic pupil size > 7.0 mm.
结局指标
主要结局
Maintenance of BCDVA -
时间窗: through study completion, an average of 1 year
lines lost \<5% of eyes with a loss of \>2 lines of BCDVA at the stability visit
Induced manifest refractive astigmatism
时间窗: through study completion, an average of 1 year
\<5% of eyes with induced manifest refractive astigmatism greater \>2 diopters at the stability visit
次要结局
未报告次要终点
研究者
相似试验
已完成
2 期
A Six Week Topical Cream Study for Subjects With Ichthyosis VulgarisIchthyosis VulgarisNCT03173547Crown Laboratories, Inc.80
Unknown
2 期
The Efficacy and Safety of a Single 70% Glycolic Acid Peel With Vitamin C for the Treatment of Acne ScarsAcne ScarsNCT02126657National University Hospital, Singapore10
已完成
2 期
Study of LX3305 in Subjects With Active Rheumatoid Arthritis on Stable MethotrexateRheumatoid ArthritisNCT00903383Lexicon Pharmaceuticals208
进行中（未招募）
1 期
A Phase 2 Study of Tarlatamab in Patients with Small Cell Lung Cancer (SCLC)EUCTR2021-002566-40-ATAmgen Inc.160
进行中（未招募）
1 期
A Phase 2 Study of Tarlatamab in Patients with Small Cell Lung Cancer (SCLC)Relapsed/Refractory Small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code 10041070Term: Small cell lung cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-002566-40-GRAmgen Inc.160